Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is experiencing growth in the pet economy and smart medical sectors, benefiting from the depreciation of the RMB and being a newly listed stock under the registration system [2]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment [3][7]. - The company was established on November 15, 1982, and was listed on January 22, 2025 [3][7]. - The main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, up 18.50% year-on-year [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, with an average of 2,456 circulating shares per person, an increase of 19.98% [8]. Market Position and Trends - The company participated in the 97th WVC annual conference, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and engaging with industry experts [2]. - The company’s overseas revenue accounted for 55.26% of total revenue, benefiting from the depreciation of the RMB [2]. Shareholder Composition - As of June 30, 2025, the largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 1.9127 million shares, followed by Southern Zhongzheng 1000 ETF with 514,500 shares [9].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., specializes in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a significant focus on the pet economy and smart medical technology [2][3][7]. Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and went public on January 22, 2025. It is recognized as a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound (71.16%), industrial ultrasound (17.30%), accessories (5.72%), X-ray (4.56%), and others (1.26%) [7]. Financial Performance - For the first half of 2025, the company achieved a revenue of 184 million yuan, representing a year-on-year growth of 15.00%. The net profit attributable to the parent company was 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the company had a total of 22,300 shareholders, a decrease of 16.65% from the previous period, while the average circulating shares per person increased by 19.98% [8]. Market Position and Trends - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company is involved in various concept sectors, including nuclear power, medical devices, smart healthcare, and newly listed stocks [7]. Recent Developments - The company participated in the 97th WVC Annual Conference from March 3 to 5, 2025, showcasing its innovative veterinary medical imaging achievements and engaging with industry experts [2]. - The company has developed a "Hongyun" system for portable ultrasound and DR devices, enabling remote image transmission and online diagnostic guidance through its "Mali Doctor" platform [2][3]. Stock Performance - On September 4, 2025, the company's stock price fell by 1.18%, with a trading volume of 84.1682 million yuan and a turnover rate of 5.71%, resulting in a total market capitalization of 10.738 billion yuan [1]. - The average trading cost of the stock is 27.20 yuan, with the current price approaching a resistance level of 25.49 yuan, indicating potential for upward movement if this level is breached [6].

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, benefiting from the pet economy and the depreciation of the RMB [2][3]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025. It is a national key high-tech enterprise [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company has a significant overseas revenue share of 55.26%, benefiting from the depreciation of the RMB [3]. Group 2: Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 184 million yuan, a year-on-year increase of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, a year-on-year increase of 18.50% [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [9]. Group 3: Market Activity - On September 1, the company's stock rose by 0.69%, with a trading volume of 95.83 million yuan and a turnover rate of 6.26%, resulting in a total market capitalization of 11.27 billion yuan [1]. - The stock has seen a net outflow of 205,000 yuan from major funds today, with a continuous reduction in major fund holdings over the past three days [4][5].

Group 1 - The company announced that its second supervisory board meeting approved multiple proposals, including the "2025 Semi-Annual Report" and its summary [2]

Group 1 - The core point of the article is that Chao Yan Co., Ltd. announced the approval of multiple proposals, including the revision of the company's articles of association, during the ninth meeting of its second board of directors [2] Group 2 - The announcement was made on the evening of August 27 [2] - The meeting involved significant corporate governance decisions that may impact the company's operational framework [2] - The specific details of the revised articles of association were not disclosed in the announcement [2]

Core Viewpoint - The company announced the appointment of new senior management personnel to support its operational development needs [1] Group 1: Management Appointments - The company held its second board meeting on August 26, 2025, where it approved the appointment of new senior management [1] - Zheng Yanna and Li Bin were appointed as executive vice presidents, while Li Bohan and Lin Jinhao were appointed as vice presidents [1] - The term for these appointments will last until the end of the current board's term [1]

Core Viewpoint - The company, Shantou Ultrasonic Instrument Research Institute Co., Ltd., is engaged in the research, development, production, and sales of medical imaging equipment and industrial non-destructive testing equipment, with a focus on the pet economy and smart medical technology [2][3][7]. Group 1: Company Overview - Shantou Ultrasonic Instrument Research Institute Co., Ltd. was established on November 15, 1982, and was listed on January 22, 2025 [7]. - The company's main business revenue composition includes: medical ultrasound 71.16%, industrial ultrasound 17.30%, accessories 5.72%, X-ray 4.56%, and others 1.26% [7]. - The company is classified under the pharmaceutical and biological industry, specifically in medical devices, and is recognized as a national key high-tech enterprise [7]. Group 2: Financial Performance - For the first half of 2025, the company achieved operating revenue of 184 million yuan, representing a year-on-year growth of 15.00%, and a net profit attributable to shareholders of 68.45 million yuan, with a year-on-year increase of 18.50% [8]. - As of June 30, 2025, the number of shareholders decreased by 16.65% to 22,300, while the average circulating shares per person increased by 19.98% to 2,456 shares [8]. - The company has distributed a total of 43.69 million yuan in dividends since its A-share listing [8]. Group 3: Market Dynamics - The company benefits from the depreciation of the RMB, with overseas revenue accounting for 55.26% of total revenue [3]. - The company participated in the 97th WVC annual meeting, showcasing innovations in veterinary medical imaging for pets, horses, and livestock, and gained valuable insights from industry experts [2]. Group 4: Technical Analysis - The average trading cost of the company's shares is 27.99 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6]. - The current stock price is near a support level of 26.85 yuan, and if this support is breached, it may trigger a downward trend [6]. Group 5: Investment Sentiment - The stock experienced a decline of 2.68% on August 27, with a trading volume of 206 million yuan and a turnover rate of 12.85%, resulting in a total market capitalization of 11.514 billion yuan [1]. - The main capital flow showed a net outflow of 4.67 million yuan, indicating a reduction in main capital positions over three consecutive days [4][5].

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 部分募投项目增加实施主体及募集资金专户 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法（2025 修正）》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》《上市公司募集资金监管 规则》等有关规定，对超研股份部分募投项目增加实施主体及募集资金专户事项进行 了审慎核查，发表核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元，募集资金总额 为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募 集资金净额 ...

中国银河证券股份有限公司 关于汕头市超声仪器研究所股份有限公司 使用募集资金置换投入募投项目的自筹资金 的核查意见 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为汕头市 超声仪器研究所股份有限公司（以下简称"公司"或"超研股份"）首次公开发行股 票并上市的保荐人，根据《证券发行上市保荐业务管理办法（2025 修正）》《深圳证 券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作（2025 年修订）》《上市公司募集资金监管 规则》等有关规定，对超研股份使用募集资金置换投入募投项目的自筹资金事项进行 了审慎核查，发表核查意见如下： 一、募集资金的基本情况 经中国证券监督管理委员会《关于同意汕头市超声仪器研究所股份有限公司首次 公开发行股票注册的批复》（证监许可〔2024〕1391 号）同意注册，公司已完成首次 公开发行人民币普通股（A 股）64,249,446 股，每股发行价格 6.70 元，募集资金总额 为人民币 430,471,288.20 元，扣除发行费用 46,108,086.88 元（不含税），公司实际募 集资金净额 ...

Core Viewpoint - The company reported a revenue of 184 million yuan for the first half of 2025, reflecting a year-on-year growth of 15.00% [1] - The net profit attributable to shareholders reached 68.45 million yuan, marking an 18.50% increase compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 65.19 million yuan, showing a significant growth of 30.11% year-on-year [1] - The basic earnings per share stood at 0.16 yuan [1]